T1	Intervention 0 61	Peripheral intravenous line survival and phlebitis prevention
T3	Intervention 96 131	antibiotics: heparin/hydrocortisone
T2	Intervention 189 207	in-line filtration
T4	Intervention 229 250	heparin/hydrocortison
T5	Intervention 269 276	nfusate
T6	Intervention 286 306	phlebitis prevention
T7	Intervention 311 372	intravenous (i.v.) line survival in peripheral i.v. catheters
T8	Intervention 404 445	patient group receiving prolonged courses
T9	Intervention 454 465	antibiotics
T10	Intervention 467 496	Analysis of the two endpoints
T11	Intervention 501 534	conventional short i.v. catheters
T12	Intervention 625 676	Patients with cystic fibrosis receiving intermitten
T13	Intervention 683 694	antibiotics
T14	Intervention 736 741	drugs
T15	Intervention 783 801	drug-free infusate
T16	Intervention 847 854	heparin
T17	Intervention 869 883	hydrocortisone
T18	Intervention 893 907	Infusion sites
T19	Intervention 942 970	the hep/hc and filter groups
T20	Intervention 996 1037	phlebitis incidence and i.v. line surviva
T21	Intervention 1073 1093	short and long lines
T22	Intervention 1125 1171	prolonged survival times and reduced phlebitis
T23	Intervention 1186 1197	short lines
T24	Intervention 1232 1244	i.v. filters
T25	Intervention 1296 1312	i.v. antibiotics
T26	Intervention 1350 1359	phlebitis
T27	Intervention 1406 1412	hep/hc
T28	Intervention 1425 1454	filters in this patient group
T29	Intervention 1479 1499	terms of ease of use
T30	Intervention 1527 1550	hep/hc-related problems
T31	Intervention 1552 1562	Long lines
T32	Intervention 1595 1606	short lines
T33	Intervention 1611 1653	patients requiring longer term i.v. access
